Cellular Dynamics has struck a deal with AstraZeneca, agreeing to provide stem cells for AZ's drug-discovery efforts.
Last year, growth in the CRO world was mostly flat, but analysts at Sterne, Agee & Leach say contract researchers could be posied for growth in 2013.
India's clinical trial regulations (or lack thereof) have long been the subject of international debate, and now the country's National Commission for Protection of Child Rights is looking to enact standardized rules for trials on children, saying many are subjected to studies without their parents being made aware.
WuXi PharmaTech and PRA are joining forces to launch an independent CRO in China, combining their capacities in the country to create a jointly owned venture for Phase I-IV clinical trial services.
After months of rumors, ShangPharma is pulling the trigger on a deal that will take it private, creating a parent company that unites private equity firms and some of the CRO's leadership.
San Francisco's goBalto has pulled in $12 million in Series B financing to advance its cloud-based clinical development platform, which allows sponsors and CROs to monitor and collaborate on study results.
Parexel International is looking to bolster its regulatory consulting business, spending $72 million on Liquent, maker of software solutions for submissions and registrations.
With T's crossed and I's dotted, CDMO Patheon has closed its $255 million acquisition of Banner Pharmacaps, maker of gelatin-based dosage forms.
We've seen countless headlines about CROs teaming up with universities on drug discovery and clinical trials, but here's a novel arrangement: Texas Tech is looking to launch a CRO of its own through a local business accelerator.
Canada's Warnex has sold off its final business unit, closing a deal that ships its bioanalytical services division to Biotrial Research for about $6.1 million, and now it has to decide whether to liquidate or regroup.
Investors were none too pleased with Charles River Laboratories' outlook for 2013, as the CRO fell as much as 8% after projecting growth below analyst estimates.
Catalent has signed a deal to provide biosimilar cell lines to Japan's UMN Pharma, a development and manufacturing agreement designed to jump-start the CMO's presence on the Asian market.
AstraZeneca is reaching out to Quintiles as it gathers data on AZD6765, part of a newfangled class of depression drugs that promises to beat what's on the market.
Perceptive Informatics, Parexel International's eClinical unit, has opened a customer care office in Shanghai to assist its digital trial management clients there and help drive adoption of its products in the country.
Swedish CRO TFS International is buying up Dimensione Ricerca, an Italian contract researcher, aiming to expand its European capabilities for cross-continent, late-stage clinical trials.
Swedish CDMO Recipharm is banking on a growing demand for analytical drug development services, planning to reconstruct its Solna, Sweden, facility to house its data-based offerings.
Covance picked up a Good Laboratory Practice Certificate for its Shanghai early development facility, a regulatory milestone the CRO says gives it a leg up on global competitors.
Alimera Sciences is facing an uphill battle getting its chronic diabetic macular edema drug on shelves in Europe, and now the company has recruited Quintiles to manage the European launch of Iluvien.
Amid budget-slashing and restructuring, AMRI has some good news to report: The CRO has re-signed with GE Healthcare to supply materials for diagnostic imaging, locking down its biggest commercial supply client through 2016.
CMO NextPharma has sold its U.S. manufacturing operation, Bioserv, to private equity player KESA Partners for an undisclosed sum, planning to focus on its core European operation.